| 3.14 -0.06 (-1.88%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.58 | 1-year : | 8.44 |
| Resists | First : | 5.63 | Second : | 7.23 |
| Pivot price | 3.95  |
|||
| Supports | First : | 3.06 | Second : | 2.54 |
| MAs | MA(5) : | 3.19 |
MA(20) : | 4.31 |
| MA(100) : | 7.36 |
MA(250) : | 19.25 |
|
| MACD | MACD : | -0.8  |
Signal : | -0.7 |
| %K %D | K(14,3) : | 2.7 |
D(3) : | 1.8 |
| RSI | RSI(14): 29.7 |
|||
| 52-week | High : | 55.59 | Low : | 3.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XAIR ] has closed above bottom band by 24.6%. Bollinger Bands are 8.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.27 - 3.29 | 3.29 - 3.3 |
| Low: | 3.05 - 3.07 | 3.07 - 3.09 |
| Close: | 3.1 - 3.14 | 3.14 - 3.17 |
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Thu, 10 Sep 2026
XAIR: Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned - TradingView
Thu, 10 Sep 2026
XAIR: Generation 2 enables immediate entry into the $400M U.S. transport market upon FDA approval - TradingView
Wed, 02 Sep 2026
At the Waldorf Astoria, Beyond Air joins a healthcare conference Sept. 10 - Stock Titan
Wed, 02 Sep 2026
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Mon, 31 Aug 2026
Beyond Air Announces FDA Breakthrough Device Designation for LungFit GO in NTM-PD Treatment - Quiver Quantitative
Tue, 25 Aug 2026
Beyond Air, Inc. SEC Filing (Aug 25, 2026) | XAIR EFFECT - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | 313.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | -374 % |
| Return on Assets (ttm) | -57.5 % |
| Return on Equity (ttm) | -519.6 % |
| Qtrly Rev. Growth | 0.5 % |
| Gross Profit (p.s.) | 0.32 |
| Sales Per Share | 7.81 |
| EBITDA (p.s.) | -25.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | 0.01 |
| PEG Ratio | 0 |
| Price to Book value | 1.16 |
| Price to Sales | 0.4 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|